Orexa

Orexa is a clinical-stage pharmaceutical company that develops and commercializes therapeutics to increase food intake. Its lead compound is a proprietary oral formulation for human use, based on a well known anesthetic. The company is in preparation for phase 2a studies in Post-Operative Ileus, Anorexia and Cachexia, three indications whereby increased food intake could lead to an improved patient health, a shorter hospital stay and significant cost savings. Orexa was founded in 2016 and is headquartered in Herpen (Oss Region, Noord Brabant), The Netherlands.

Team:

Sake Stevenhaagen

Sake Stevenhaagen

CEO / CFO

Investor

Actuarial Sciences (University of Amsterdam)

 

Former:

Early investor in AM-Pharma.

CFO of Alloksys Life Sciences

Venture Partner of NextStage Early Stage Fund

Ard Peeters

Ard Peeters

CSO / Founder of Orexa

Biologist
PhD in Psychology
Professor in Behavioural Pharmacology (Radboud UMC, Nijmegen)

 

Former:

Organon, Schering Plough, MSD

Within Organon Ard was responsible for the development of brain active (CNS) drugs.

“We have found a very strong signal in our pre-clinical research and successfully completed a Phase 1 study.

Now we are in the most exciting stage: will our mechanism of action also work in patients in Phase 2 ?”

Prof. Dr. Ard Peeters

CS0 and founder of Orexa

Developing a medicine that increases food intake.